Citable filing context
ZBH's research view summarizes recent SEC filing context, starting with management_change from Sep 8, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 8, 2026 | management_change | Zimmer Biomet announced the departure of Group President Kevin Thornal and the promotion of three commercial leaders. |
| Aug 5, 2026 | earnings | Zimmer Biomet reported Q2 2026 net sales of $2.177 billion and updated its full-year 2026 financial guidance. |
| Aug 5, 2026 | other | Zimmer Biomet Holdings, Inc. filed an 8-K report regarding financial exhibits and other events. |
| Aug 5, 2026 | Guidance: adjusted_diluted_eps | 8.47 to 8.59 |
| Aug 5, 2026 | Guidance: constant_currency_revenue_change | 3.40 to 4.40 |
| Aug 5, 2026 | Guidance: net_sales_growth | 2.50 to 4.50 |
| Aug 5, 2026 | mda_quarterly | ZBH reported net sales growth of 4.8% and 7.0% for the three and six-month periods ended June 30, 2026, respectively. Performance was bolstered by the acquisition of Paragon 28, increased sales of ROSA® robots and bone cement, and favorable foreign currency impacts. While the company saw volume growth, global selling prices faced a 0.7% to 0.8% headwind due to hospital cost-containment efforts and volume-based discounting. Operating profit benefited from the non-recurrence of 2025 acquisition costs and restructuring savings, alongside a $30 million U.S. tariff refund. However, profitability was pressured by inflation, higher interest expenses, and increased investments in the U.S. commercial sales channel. The company’s S.E.T. (Sports Medicine, Upper Extremities, Trauma) category was a primary growth driver, significantly aided by the Paragon 28 integration. Liquidity remains stable with $410 million in cash and significant undrawn revolving credit facilities. Management expects 2026 full-year sales growth of 3.9% to 4.9%, though they caution that go-to-market strategy shifts and the timing of capital sales could cause quarterly volatility. Key risks include ongoing litigation, potential tax adjustments, and the integration of recent acquisitions, including a $245 million deal closed subsequent to the quarter. |
| May 1, 2026 | mda_quarterly | Net sales for the three-month period ended March 31, 2026, increased 9.3% to $2.09 billion, driven by the Paragon 28 acquisition, ROSA Robot and bone cement sales, and a 2.5% positive foreign currency impact. Net earnings rose to $238.1 million, bolstered by a $30 million U.S. tariff refund and reduced R&D spending following the completion of EU Medical Device Regulation compliance. Full-year 2026 net sales growth is projected between 2.5% and 4.5%. Product growth was led by the S.E.T. category (19.5%) and Technology & Data, Bone Cement and Surgical (14.6%), while pricing pressures from healthcare cost containment created a 0.4% headwind. Operating profit is expected to increase through leverage and restructuring savings, though partially offset by inflation and U.S. commercial sales investments. The 2025 Restructuring Plan targets $175 million in annual pre-tax operating expense reductions by 2027. As of March 31, 2026, ZBH held $424.2 million in cash against $7.47 billion in total debt, with $1.18 billion maturing by February 2027. The company also authorized a $1.5 billion share repurchase program. |
Source: SEC EDGAR filing text and events; period Sep 8, 2026; filed Sep 8, 2026.
ZBH company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.